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1 Introduction
The European Union has been confronted with
a phenomenon called knowledge paradox (Pavitt
2000). The high quality of research at universities
and research institutions has not been translated
into commercial applications in a sufficient way.
Licensing is the established way to transfer tech-
nology from universities and research institutions
to the commercial sector. But licensing is only appli-
cable when technologies can be protected by
patents (Hearn 1981). If the technology is not mature
enough to establish strong IP rights, the commer-
cialization of the technology is difficult. Besides
licensing, academic spin-offs from universities and
research institutions can be used for technology
transfer (Franklin et al. 2001). Despite the fact that
normally licensing is short-term financially more
attractive, the ownership of equity in spin-offs may
increase the potential up-side gain and is an attrac-
tive option to universities and research institutions.
Taking equity in a spin-out company can produce
a greater average return in the long run compared
to licensing business (Bray and Lee 2000). 
This paper investigates the creation of new ven-
tures like spin-offs and spin-outs as a method for
technology transfer from universities and research
institutions to companies and between companies.
Additionally, the approach of internal start-ups for
company internal technology transfer, which is not
yet described in the scientific literature, was iden-
tified during our research. The paper specifically
seeks to address the following research questions.
RQ1? How was the maturity of the technologies
increased within the new ventures?
RQ2? How were additional resources acquired
by the new ventures?
RQ3? Which technology transfer results were
achieved by the new ventures?
The chemical and pharmaceutical sectors as
mature industries were selected as they rely on
effective and efficient technology transfer to main-
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tain their global competitiveness. They are global-
ly one of the largest manufacturing industries with
strong impact on other industries. The regional
focus was on the two countries Germany and
Switzerland with a globally very strong chemical
and pharmaceutical industry. This regional focus
was chosen to have the same general cultural back-
ground which makes the analysis of the organiza-
tional, managerial, financial and cultural similari-
ties and dissimilarities more reliable.
Section 2 of this paper provides the theoretical
background according to academic spin-offs and
corporate spin-outs. The methodology is described
in section 3, the results and discussions are shown
in section 4 and the implications and conclusions
in section 5.
2 Theoretical background
2.1 Academic spin-offs 
Technology transfer through the creation of
academic spin-offs is important especially in high-
tech areas (Shane 2002; Heirman and Clarysse 2004;
Stam et al. 2009). There has been a substantial
increase in the number of academic spin-offs cre-
ated in Europe (Wright et al. 2004; Moray and
Clarysse 2005; Clarysse et al. 2007). This is based
on a change in government policies that encour-
age universities and research institutions to com-
mercialize their research results. Besides teaching
and research, it is a mission for universities and
research institutions to support economic and social
development by commercializing the output of
basic research through technology transfer
(Etzkowitz et al. 2000; Etzkowitz 2003). 
In the United States, the Bayh-Dole Act has grant-
ed the institutions, in which research is conducted
using governmental funds, ownership of their
research outcome in order to support their com-
mercial application (European Commission 2003;
Grimaldi et al. 2011). In consequence, the enactment
of the Bayh-Dole Act in 1980, accompanied by other
measures (Popp Berman 2008), had been substan-
tially enhanced the commercialization of technolo-
gies developed at universities and research insti-
tutions. In contrast in Europe the legislative coun-
terparts were lagging behind for about 20 years
(Grimpe and Fier 2010) and the policy approaches
are very heterogeneous (Mustar et al. 2008; Wright
et al. 2008). Following the United States model,
several European countries adopted comparable
policies aimed at encouraging a more active role
for academic institutions in technology transfer
(Grimaldi et al. 2011) on national level, while other
countries have acted in exactly the opposite way.
In line with Bayh-Dole, Germany made an equiv-
alent step through the abolishment of the so-called
professors’ privilege in 2002, which had granted
the scientists the right to claim ownership of the
research outcome of their scientific work, even if
the underlying research was funded by public money
designated to the university. In the same year, how-
ever, Italy, has newly introduced the professors’ priv-
ilege. In contrast to these regulations on national
level, in other European countries such as the Unit-
ed Kingdom each university has defined its own
rules in respect of the ownership of the research
results (Czarnitzki et al. 2009). 
Founding a start-up out of a university or
research institution is a special challenge for entre-
preneurs. Normally academic researchers do not
have the knowledge, expertise or experience to
commercialize their research results (Litan and
Mitchell 2007). Therefore, many universities and
research institutions have implemented technol-
ogy transfer offices (TTOs), entrepreneurship cen-
ters and incubators (Goldfarb and Henrekson 2003;
Bercovitz and Feldmann 2006; Rasmussen et al.
2006). These TTOs recognise start-ups as an inter-
esting method of technology transfer and thus help
scientists in their entrepreneurial efforts (Mark-
man et al. 2005; Meyer 2006). It is important that
universities and research institutions have clear
strategies towards spin-off activities (Lockett et al.
2003). This includes the build-up of expertise and
networks as well as the allocation of sufficient
resources to realize the strategy in a professional
way.
2.2 Corporate spin-outs 
Whereas the term R&D spin-off stands for a
new company based on the findings of members
of a research group from academia, the common
definition of spin-out is when a part (department,
business unit division or even a project team) of a
company or organization becomes an independ-
ent business (De Cleyn and Braet 2009; Mustar et
al. 2006). But the two terms are not always used
unambiguously, as sometimes the term corporate
spin-off is used for a small company which has
been split-off from a larger, parent organization.
Following a merger or simply complementing a
strategic realignment on core areas, spin-outs pro-
vide an option to leverage assets of low strategic
importance, or underexploited assets in their par-
ent companies. The spin-out company takes per-
sonnel, assets, IP, technology, and existing products
from the parent organization. In many cases the
management team of the new company originates
from the same parent organization. A corporate
spin-out may initially face fewer difficulties than
an academic spin-off, because companies, as par-
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ent organisations, could assist a start-up compa-
ny better than universities and research institu-
tions (Jagersma and van Gorp 2003). The parent
company provides the necessary assets and IP and
an external investor finances the liquidity of the
new start-up. 
In the case of redundant capacities or non-core
activities (e.g. after a merger of two companies), a
spin-out can be used to reduce capacities and costs
as an alternative to closing or selling the unit
(Parhankangas and Arenius 2003; Bergh and Lim
2008). The reduction of capital requirements and
risk, if R&D projects are not in the strategic focus
of a company, can be another reason (Chemmanur
and Yan 2004). As many areas of the R&D process
chain can be outsourced and covered by external
service providers, they will play a more important
role in industrial R&D. Service oriented spin-offs
and spin-outs contribute towards this, as these pro-
vide highly specialized services. Therefore, spin-
outs can also be used as a method to make R&D
more flexible for increased effectiveness and effi-
ciency (Krishnaswami and Subramaniam 1999).
3 Methodology
3.1 Research approach and quality
The research method used in this study was the
case study approach, due to its many benefits. It
represents a combination of learning just by watch-
ing (Helper 2000) with the main advantage being
that the object of study is studied in real life con-
text (Yin 1981). Flyvberg (2006) states that “the case
study produces the type of context dependent
knowledge that research on learning shows to be
necessary to allow people to develop from rule-
based beginners to virtuoso-experts”.
In contrast to the single case study approach,
which aims at falsifying theoretical insights or to
provide new insights in unexplored phenomena
(Yin 2003; Yin 2006), many authors consider results
from multiple case studies as more convincing,
trustworthy, and robust (Eisenhardt 1989; Yin 2006).
Therefore, the multiple case study approach was
applied in this research, which compares cases and
highlights resulting insights through similarities
and dissimilarities between them. The cases were
selected on an objective of maximum variation,
thus enabling us to obtain information on the sig-
nificance of various circumstances for the identi-
fied case studies (Flyvbjerg 2006). 
In order to gain a better understanding of actu-
al events and to avoid the influence of personal
views and theoretical perspectives on the data col-
lection, interviews based on a narrative approach
(Polkinghorne 1988; Czarniawska 1998; Pentland
1999) were conducted, whereby the interviewees
described their role with little interruption from
the interviewer. To develop the case studies, semi-
structured interviews were used as well as the inclu-
sion of various sources of qualitative and quanti-
tative data, such as document and literature analy-
sis and observations (Yin 2006). As suggested by
Eisenhart (1989), data triangulation was used to
help achieve a more holistic view of the case stud-
ies. With the different rounds of interviews and the
combination of the various sources of information
collected over a long period of time, an in-depth
description of the different technology transfer
approaches was obtained.
Quality assurance is important when conduct-
ing explorative research applying a multiple case
study approach and analysing qualitative data
research (Bortz and Döring 2005; Yin 2006; Corbin
and Strauss 2008; Lamnek 2008). As Yin (2006) stat-
ed, reliability of qualitative research can only be
achieved by a structured way of proceeding and by
exactly documenting the research process and its
results. Since there can be no validity without reli-
ability, a demonstration of validity is sufficient to
establish reliability, so that reliability is a conse-
quence of the validity in a study (Patton 2002).
3.2 Data collection and analysis
Between 2004 and 2006, literature research on
academic spin-offs, corporate spin-outs and their
application for technology transfer in both aca-
demic and practitioner oriented journals as well as
the internet was carried out. With the information
collected, a database was obtained with interest-
ing examples from two industries (chemicals and
pharmaceuticals) and two technologies (biotech-
nology and nanotechnology) in Germany and
Switzerland. From this database, 15 academic spin-
offs, 12 corporate spin-outs, 16 universities and
research institutions as well as 6 TTOs, 25 compa-
nies and 23 venture capitalists (VCs) including cor-
porate VCs were selected based on their fit to the
research scope and their interest in and availabil-
ity for an interview. Narrative interviews were con-
ducted with them between 2006 and 2008. One-
on-one interviews of approximately one hour were
conducted in an unstructured, open-end way with-
out any formal questionnaire. Prior to the inter-
view, the interviewer collected in-depth informa-
tion on the company or institution through vari-
ous public sources (e.g. databases, website, press
releases) to enable an efficient conduct of the inter-
views.
The selection of case studies from the inter-
views for the research was based on an objective
of maximum variation to cover the whole range of
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cases, the potential to obtain appropriate answers,
and the willingness to further participate in this
study. Table 1 shows details of the 12 selected case
studies from Germany and Switzerland: 5 case stud-
ies each for academic spin-offs and corporate spin-
outs and 2 for internal start-ups (see appendix).
The same interviewer conducted again one-on-one
interviews with the 12 selected case studies between
2008 and 2009. This time semi-structured inter-
views were used in order to develop these 12 case
studies, whereby a reference set of questions was
developed as a guideline for the interview, which
allowed room for spontaneous answers. The ques-
tions were structured around different topical
groups, like basic data regarding the case studies
(parent institution and technology owner, involved
parties), background for creating a new venture
(reasons and strategy, relevance of technology trans-
fer aspects), realization of the a new venture (con-
ceptual design, engagement of investors, spin-
off/spin-out process) and the results of these activ-
ities (development of the new venture, achieve-
ment of technology transfer goals).
The results of these semi-structured interviews
as well as the narrative interviews were analysed
and compared regarding the research questions.
Additional secondary data was collected from the
interviewees and through internet research for all
the case studies. To identify relevant scientific lit-
erature and to update the case studies, a final lit-
erature research was conducted in the first half of
2011.
4 Results and discussions
4.1 Maturity of the technology
Within all analysed academic spin-offs the matu-
rity of the technology was not sufficient to direct-
ly commercialize the technology. Table 2a shows
the case specific mix of the identified aspects caus-
ing the need for further development of the tech-
nology and Table 2b case study specific details (see
appendix). 
All case studies had proof-of-concept only at
laboratory scale with missing upscaling know-how
to realize technical scale. Other aspects are no cost
effective production processes, so that the new
products cannot be produced on a cost competi-
tive level, low relevance for industrial applications
or insufficient performance. If there is no customer
feedback, due to a missing prototype or access to
customers, the customer acceptance of the new
products is unclear. Further R&D is also necessary,
if the new products have no competitive advan-
tage in the eyes of the customers. No validation for
commercial use and no fulfilled regulatory hurdles
are also reasons for additional R&D activities. Case
study B had a production technology for new nano-
materials only in laboratory scale without any
expertise and experience for upscaling into the
technical scale. The further R&D work focused on
the upscaling of the laboratory process into a tech-
nical feasible process and development of formu-
lations for a customer from the consumer indus-
try. The result was a cost effective production process
for a broad range of nanomaterials and formula-
tions which could be directly used by the customer.
The identified kinds of further R&D work showed
typical aspects. Equipment development means
developing hardware and software for the cost effi-
cient implementation of a new technology in the
industry. Of importance is also upscaling of pro-
duction processes through process development
and the development of a cost effective produc-
tion process. The improvement of performance
enables the implementation in the industry. Scien-
tific understanding of key aspects enables to
improve the performance and to fulfil regulatory
requirements. Other aspects are the development
of industrial applications (e.g. implementation of
products and technologies in the industry), the
development of special grades or formulations for
technical applications and the development of mar-
ketable products or service offerings. All these
aspects were relevant for case study D. The devel-
opment of industrial relevant strains for the proof
of the genetic tools to modify microorganisms for
the production of biofuels and bio-based chemi-
cals was the critical step to get an industrial rele-
vant strain with sufficient performance (yield,
robustness) to produce ethanol in world scale pro-
duction plants. Also within case study E, the improve-
ment of biocatalysts in selected technical process-
es together with industrial partners was necessary
to develop biocatalytic systems used in industrial
applications with high performance and lower pro-
duction costs compared to established chemical
systems.
Typical results of the further R&D activities could
be identified. An example for the importance of
equipment for industrial applications and of pro-
viding of fee-for-service work is case study A. The
high throughput experimentation technology had
at the university only proof-of-concept in labora-
tory scale and high operational costs in industrial
applications due to low automation of the process.
The development of high throughput experimen-
tation equipment enabled the spin-off to provide
fee-for-service work for industrial customers and
to sell the equipment to these customers. Other
results were cost effective production processes
for larger quantities, formulations for customer
specific solutions and validated systems with cer-
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tification. 
The aspects describing the need for further R&D
work in the case of corporate spin-outs and inter-
nal start-ups were rather similar to academic spin-
offs, i.e. there is no clear difference between the
three groups. Also, the kinds and the results of fur-
ther R&D work were very similar in the three groups
of case studies. Case study H shows that the cor-
porate spin-out enabled the further development
of selected technologies and correlated services
based on scientific expertise. The result was a world-
wide well-known provider of special pharma devel-
opment services with strong teams consisting of
scientists and marketing and sales experts. The
described aspects were also relevant for case study
K. The new nanomaterials from the laboratory were
not really relevant for the industry as the particle
size and the application properties were not suit-
able for industrial processes. Further R&D work of
the internal start-up together with the business
units of the parent company solved these prob-
lems. Another result was the cost effective produc-
tion process for a broad range of nanomaterials
and formulations which could be directly used by
the consumer company in their products.  
4.2 Acquisition of additional resources 
Clear differences can be seen in the three groups,
academic spin-offs, corporate spin-outs and inter-
nal start-ups, with regard to the acquisition of addi-
tional resources to realize the additional R&D work.
Table 3a shows the identified aspects and table 3b
the case study specific details (see Appendix). 
Academic spin-offs need additional resources
because there is no academic interest in further
R&D, the topics are out of scope of universities or
there are not enough resources at universities.
Financing of additional resources is made by indus-
trial partners, VC and corporate VC as well as strate-
gic investors. Case study E showed the need for
additional resources at universities in areas which
are out of scope and not interesting from an aca-
demic point of view. The cost intensive further R&D
work to develop industrial relevant biocatalysts
could not be financed by the universities as tech-
nology owner and was financed by VC. Case study
D is an example for a technology development with-
in the academic scope of the university but where
the necessary resources were not available at the
university and a strategic investor financed these
resources. Case studies A, B and C were examples
of an investment of industrial partners who worked
along with their investment also operationally close
with the academic spin-off. The main reasons for
investment are large market potentials and the
opportunity of a trade sale or initial public offer-
ing (IPO) attracting strategic and VC investors.
For more and more non-core R&D projects in indus-
trial companies there are not enough company
internal resources (capital, management capacity)
available resulting in the divestment of these proj-
ects. The need for additional resources for corpo-
rate spin-outs is caused by this divestment process
from the parent company. In the case of corporate
spin-out J, the parent organization spun-out parts
of the clinical research department as an alterna-
tive to closing down operations. Another possible
reason to realize a spin-out is the isolation of high
risk projects, in order to protect the parent compa-
ny from these risks, like in the case of case study G.
The divestment of a drug development project by
the parent company was the result of company
internal problems during the development process
which increased the further development risk sig-
nificantly. These spin-outs enable companies to
concentrate on their core activities, without hav-
ing to abandon new products coming from these
projects. As in the case of academic spin-offs, the
additional resources are financed by industrial part-
ners, VC including corporate VC and strategic
investors. Reasons for the investment are, besides
the opportunity of a trade sale or IPO, the realiza-
tion of value creation potentials and to provide flex-
ible services for the parent company. Case study H
was the divestment of a pharma service depart-
ment after the merger of two pharma companies.
The spin-out was realized by the corporate VC
department of the parent company together with
strategic investors with pharma experience. A major
intension of the parent company was, despite the
reduction in headcount, to further use parts of the
services which were no longer available inhouse
on a flexible basis. Case study J was the divestment
of parts of the clinical research department of a
pharma company after the merger with another
pharma company. Aim was the creation of a lead-
ing clinical research organization to further use
these services.
The situation of internal start-ups is rather differ-
ent compared to academic spin-offs and corporate
spin-outs. The need for additional resources is due
to the fact that the R&D work is too risky and the
market proof-of-concept is not yet shown. As there
are not enough resources in the business unit, the
financing gap is closed by corporate R&D budgets.
Within the case studies K and L, the relevant busi-
ness units within a chemical company were not
willing to finance the R&D work due to low suc-
cess probability. The additional investment by cor-
porate R&D budgets was made because there was
the possibility to bring innovative products with
over average profitability onto the market to
strengthen the existing business. Aim from a cor-
Technology transfer by new ventures within the chemical and pharmaceutical
industry
porate point of view was increased innovativeness
and the realization of growth option which could
not be realized with only the resources of the busi-
ness unit.
4.3 Technology transfer results 
The analysis of the technology transfer results
showed some similarities and dissimilarities
between the three groups. Table 4a shows the analy-
sis regarding technology transfer goal, technology
transfer impact and technology transfer success
and Table 4b some case study specific details (see
Appendix). 
In the case of academic spin-offs, the goal is the
technology transfer from universities to industri-
al partners. In all analysed cases studies, the tech-
nology transfer was successful: there were some
market introductions of new products and, in some
cases, the integration of the spin-off into an indus-
trial company. For example, in case study D, there
was a joint development of a new product and the
later acquisition of the academic spin-off by the
industrial partner. This enabled the global market
launch of a new product for ethanol by combining
the production and marketing/sales capabilities of
the buying company and the technologies of the
acquired spin-off. This is an example of the trans-
fer of a technology from a university to a compa-
ny via the purchase of the spin-off company. Case
study A shows that the technology transfer is not
only done through the sale of the spin-off but also
by acting as a service provider for industrial cus-
tomers.
Corporate spin-outs realize technology trans-
fer from the parent company as a new legal enti-
ty to further develop the technology as an alterna-
tive to closing the operations. As in the case of aca-
demic spin-offs, the technology transfer can be real-
ized by the trade sale to a new owner or by acting
as a service provider. The case studies showed in
some cases the market introduction of new prod-
ucts and in other cases the integration into a new
company. For example, case studies H and J exe-
cuted the transfer of the operations into a new
legal entity with the aim to further develop and
commercialize the services offerings. The result
was independent companies with cost competi-
tive services which were widely used by the former
parent companies as well as other customers from
the pharmaceutical industry. 
Internal start-ups, like case studies K and L, show
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Figure 1 Technology transfer by academic spin-offs, corporate spin-outs and internal start-ups.
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the technology transfer from R&D departments
into a commercial business unit. Result was in both
cases the integration of (parts of) the internal start-
up into a business unit of the parent company in
combination with the introduction of new prod-
ucts into the market.
5 Implications and conclusions
The analysis of the case studies confirmed that
the creation of new ventures could be used for tech-
nology transfer from university, research institu-
tions and companies as technology developers to
companies as technology users (figure 1). In all case
studies the maturity of the technology was not suf-
ficient to directly commercialize the technology.
Necessary was the further development of the tech-
nology to a stage interesting for established com-
panies which are looking to offer concrete prod-
ucts or services. The technical proof-of-concept has
normally to be done before investments in produc-
tion, marketing and sales are made. The need for
further R&D work is a central element of using new
ventures for technology transfer combined with
the fact that the parent organization (universities,
research institutions and companies) is not able or
willing to finance this additional R&D work. 
Academic spin-offs can especially help to trans-
fer technologies to the industry if they are out of
scope of the academic institutions or there is no
academic interest in the work. Corporate spin-outs
can be used for technology transfer as a good alter-
native to closing R&D operations if they no longer
fit into the parent organization and the technolo-
gy is not mature enough to sell it directly. Both spin-
offs and spin-outs have to acquire additional
resources from external partners like financial
investors or industrial co-operation partners to
increase the maturity of the technology. The tech-
nology transfer back to industrial companies can
work in two ways: the new ventures can work as
service provider as an independent company or be
sold and integrated into a new company. 
The principle of company internal start-ups,
which is using many elements of academic spin-
offs and corporate spin-outs, can help to improve
technology transfer from research labs of R&D
departments to commercial business units within
the same company. The internal start-up will be
integrated into an operational business unit if the
technological and market proof-of-concept is shown.
Corporate spin-outs and internal start-ups can over-
come innovation barriers like bureaucratic think-
ing, fear of cannibalism or the well-known 'not
invented here' syndrome which are normally found
within companies. 
The new ventures enable the opportunity to
combine scientific expertise with business expert-
ise of external managers or entrepreneurs. They
can more easily pick up external impulses and serve
as a mechanism to explore revolutionary ideas in
a setting apart from mainstream business. For
example, competencies from other companies or
top-class scientists from universities and research
institutions can be engaged to form excellent teams.
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Table 2b Maturity of the technology (case study specific details).
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Table 3a Acquisition of additional resources (overview).
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st
m
en
t o
f p
ar
ts
 of
 th
e c
lin
ica
l r
es
ea
rch
 de
pa
rtm
en
t
by
 th
e p
ar
en
t c
om
pa
ny
 af
te
r t
he
 m
er
ge
r w
ith
 an
ot
he
r
ph
ar
m
a c
om
pa
ny
Pa
re
nt
 co
m
pa
ny
 ha
s l
on
g-
te
rm
 st
ra
te
gi
c i
nv
es
to
r
to
ge
th
er
 w
ith
 a 
VC
 co
m
pa
ny
Ai
m
 to
 cr
ea
te
 a 
lea
di
ng
 cl
in
ica
l r
es
ea
rch
 or
ga
ni
za
tio
n
as
 al
te
rn
at
ive
 to
 cl
os
in
g t
he
 op
er
at
io
ns
 du
e t
o h
ig
h
co
st
s a
nd
 ne
ga
tiv
e i
m
ag
e a
sp
ec
ts
 
In
te
rn
al
st
ar
t-u
ps
K L
Re
lev
an
t b
us
in
es
s u
ni
ts
 w
ith
in
 th
e c
he
m
ica
l c
om
pa
ny
no
t w
illi
ng
 to
 fi
na
nc
e t
he
 de
ve
lo
pm
en
t w
or
k d
ue
 to
lo
w 
su
cc
es
s p
ro
ba
bi
lit
y
Co
rp
or
at
e R
&D
 bu
dg
et
 w
ith
in
 th
e p
ar
en
t c
om
pa
ny
m
an
ag
ed
 by
 th
e c
or
po
ra
te
 R&
D 
de
pa
rtm
en
t
Po
ss
ib
ilit
y t
o b
rin
g i
nn
ov
at
ive
 pr
od
uc
ts
 w
ith
 ov
er
 av
e-
ra
ge
 pr
of
ita
bi
lit
y o
nt
o t
he
 m
ar
ke
t t
o s
tre
ng
th
en
 th
e
ex
ist
in
g b
us
in
es
s
Table 3b Acquisition if additional resources (case study specific details).
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TTy
pe
Te
ch
no
lo
gy
 tr
an
sfe
r g
oa
l
Te
ch
no
lo
gy
 tr
an
sfe
r i
m
pa
ct
Te
ch
no
lo
gy
 tr
an
sfe
r s
uc
ce
ss
Ac
ad
em
ic 
sp
in
-o
ffs
Te
ch
no
lo
gy
 tr
an
sfe
r f
ro
m
 th
e u
ni
ve
rsi
ty
an
d f
ur
th
er
 de
ve
lo
pm
en
t t
o u
se
 it
 by
in
du
st
ria
l p
ar
tn
er
s
Tr
an
sfe
r f
ro
m
 th
e u
ni
ve
rsi
ty
to
 an
 in
du
st
ria
l c
om
pa
ny
 vi
a
a s
pi
n-
of
f (
tra
de
 sa
le 
or
 se
r-
vic
e p
ro
vid
er
)
Ye
s, b
ec
au
se
 m
ar
ke
t i
nt
ro
du
ct
io
n o
f n
ew
pr
od
uc
ts
 an
d i
n s
om
e c
as
es
 in
te
gr
at
io
n
in
to
 an
 in
du
st
ria
l c
om
pa
ny
 
Co
rp
or
at
e s
pi
n-
ou
ts
Te
ch
no
lo
gy
 tr
an
sfe
r i
nt
o a
 ne
w 
leg
al 
en
tit
y
to
 fu
rth
er
 de
ve
lo
p t
he
 te
ch
no
lo
gy
 as
 al
te
r-
na
tiv
e t
o c
lo
sin
g t
he
 op
er
at
io
ns
Tr
an
sfe
r f
ro
m
 th
e p
ar
en
t
co
m
pa
ny
 to
 th
e n
ew
 ow
ne
rs 
via
 a 
sp
in
-o
ut
 (t
ra
de
 sa
le 
or
se
rv
ice
 pr
ov
id
er
)
Ye
s, b
ec
au
se
 m
ar
ke
t i
nt
ro
du
ct
io
n o
f n
ew
pr
od
uc
ts
 an
d i
n s
om
e c
as
es
 in
te
gr
at
io
n
in
to
 an
 in
du
st
ria
l c
om
pa
ny
 (a
s w
ell
 as
 su
r-
viv
al 
of
 di
ve
st
ed
 en
tit
ies
)
In
te
rn
al 
st
ar
t-u
ps
Te
ch
no
lo
gy
 tr
an
sfe
r f
ro
m
 R&
D 
de
pa
rtm
en
t
in
to
 a 
co
m
m
er
cia
l b
us
in
es
s u
ni
t
In
te
gr
at
io
n o
f (
pa
rts
 of
) t
he
in
te
rn
al 
st
ar
t-u
p i
nt
o a
 bu
si-
ne
ss
 un
it 
of
 th
e p
ar
en
t c
om
-
pa
ny
Ye
s, b
ec
au
se
 m
ar
ke
t i
nt
ro
du
ct
io
n o
f n
ew
pr
od
uc
ts
Table 4a Technology transfer results (overview).
Gunter Festel
Journal of Business Chemistry 2013, 10 (3)© 2013 Institute of Business Administration 130
Ty
pe
Ca
se
St
ud
y
W
ha
t w
as
 th
e t
ec
hn
ol
og
y t
ra
ns
fe
r g
oa
l?
W
ha
t w
as
 th
e t
ec
hn
ol
og
y t
ra
ns
fe
r i
m
pa
ct
?
W
as
 th
e t
ec
hn
ol
og
y t
ra
ns
fe
r a
pp
ro
ac
h 
su
cc
es
sfu
l?
Ac
ad
em
ic
sp
in
-o
ffs
A
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 th
e u
ni
ve
rsi
ty
 an
d
fu
rth
er
 de
ve
lo
pm
en
t f
or
 ap
pl
ica
tio
n b
y i
nd
us
tri
al 
co
m
-
pa
ni
es
 to
 im
pr
ov
e m
at
er
ial
s R
&D
Ch
em
ica
l c
om
pa
ny
 as
 m
ajo
rit
y s
ha
re
ho
ld
er
 fo
r p
re
fe
rre
d
ac
ce
ss
 to
 th
e t
ec
hn
ol
og
y
Ye
s, b
ec
au
se
 th
e t
ec
hn
ol
og
y i
s i
nt
en
siv
ely
 us
ed
 by
 ch
em
ica
l
an
d m
at
er
ial
 co
m
pa
ni
es
B
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 th
e u
ni
ve
rsi
ty
 to
 th
e
in
du
st
ria
l p
ar
tn
er
 to
 de
ve
lo
p n
ew
 na
no
te
ch
no
lo
gy
ba
se
d p
ro
du
ct
s
Co
m
pl
et
e i
nt
eg
ra
tio
n i
nt
o t
he
 co
ns
um
er
 co
m
pa
ny
af
te
r s
uc
ce
ss
fu
l m
ar
ke
t i
nt
ro
du
ct
io
n o
f t
he
 fi
rst
 pr
o-
du
ct
s
Ye
s, b
ec
au
se
 th
e i
nd
us
tri
al 
pa
rtn
er
 in
te
gr
at
ed
 th
e s
pi
n-
of
f
af
te
r d
ev
elo
pi
ng
 th
e t
ec
hn
ol
og
y t
o a
 m
at
ur
ity
 st
ag
e w
hi
ch
co
ul
d b
e u
se
d b
y t
he
 in
du
st
ria
l p
ar
tn
er
C
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 th
e u
ni
ve
rsi
ty
 to
 th
e
in
du
st
ria
l p
ar
tn
er
 to
 im
pr
ov
e a
nd
 va
lid
at
e t
he
 te
st
in
g
sy
st
em
In
te
gr
at
io
n i
nt
o t
he
 R&
D 
de
pa
rtm
en
t o
f a
 co
sm
et
ics
co
m
pa
ny
 to
 br
oa
dl
y u
se
 th
e t
es
tin
g s
ys
te
m
 fo
r n
ew
pr
od
uc
t d
ev
elo
pm
en
ts
Ye
s, b
ec
au
se
 th
e i
nd
us
tri
al 
pa
rtn
er
 in
te
gr
at
ed
 th
e s
pi
n-
of
f a
fte
r d
ev
elo
pi
ng
 th
e t
ec
hn
ol
og
y f
or
 in
du
st
ria
l a
pp
li-
ca
tio
n o
n a
 br
oa
de
r b
as
is
D
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 th
e u
ni
ve
rsi
ty
 to
 th
e
in
du
st
ria
l p
ar
tn
er
 vi
a p
ur
ch
as
e o
f t
he
 sp
in
-o
ff 
co
m
pa
ny
Tr
ad
e s
ale
 to
 th
e i
nd
us
try
 pa
rtn
er
 to
 gl
ob
all
y l
au
nc
h t
he
pr
od
uc
t f
or
 et
ha
no
l p
ro
du
ct
io
n o
n t
o t
he
 m
ar
ke
t a
nd
 to
de
ve
lo
p o
th
er
 pr
od
uc
ts
Ye
s, b
ec
au
se
 th
e t
ec
hn
ol
og
y w
as
 th
e m
iss
in
g l
in
k f
or
 an
in
du
st
ria
l c
om
pa
ny
 to
 br
in
g a
 ne
w 
pr
od
uc
t t
o t
he
 m
ar
-
ke
t
E
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 th
e u
ni
ve
rsi
ty
 to
 th
e
in
du
st
ria
l p
ar
tn
er
s o
n t
he
 ba
sis
 of
 co
-o
pe
ra
tio
ns
Co
-o
pe
ra
tio
ns
 w
ith
 ch
em
ica
l a
nd
 ph
ar
m
ac
eu
tic
al 
co
m
-
pa
ni
es
 to
 sh
ow
 fi
rst
 te
ch
ni
ca
l s
ca
le 
ap
pl
ica
tio
ns
 of
 bi
o-
ca
ta
lys
ts
Ye
s, b
ec
au
se
 di
ffe
re
nt
 in
du
st
ria
l c
o-
op
er
at
io
n p
ar
tn
er
s
us
e t
he
 te
ch
no
lo
gy
 in
 th
eir
 pr
od
uc
tio
n p
ro
ce
ss
es
Co
rp
or
at
e
sp
in
-o
ut
s
F
Tr
an
sfe
r o
f t
he
 liq
ui
d c
ry
st
al 
te
ch
no
lo
gy
 in
to
 a 
ne
w
leg
al 
en
tit
y t
o f
ur
th
er
 de
ve
lo
p t
he
 te
ch
no
lo
gy
In
de
pe
nd
en
t c
om
pa
ny
 as
 te
ch
no
lo
gy
 le
ad
er
 in
 it
s m
ar
ke
t
se
gm
en
ts
 w
ith
 a 
br
oa
d p
ro
du
ct
 ra
ng
e a
lre
ad
y i
nt
ro
du
ce
d
in
to
 th
e m
ar
ke
t
Ye
s, b
ec
au
se
 a 
br
oa
d r
an
ge
 of
 pr
od
uc
ts
 ba
se
d o
n t
he
te
ch
no
lo
gy
 ha
s b
ee
n i
nt
ro
du
ce
d i
nt
o t
he
 m
ar
ke
t
G
Tr
an
sfe
r o
f t
he
 dr
ug
 de
ve
lo
pm
en
t p
ro
jec
t i
nt
o a
 ne
w
leg
al 
en
tit
y t
o p
ro
ce
ed
 th
e d
ev
elo
pm
en
t p
ro
gr
am
m
e
Re
in
te
gr
at
io
n i
nt
o t
he
 fo
rm
er
 pa
re
nt
 co
m
pa
ny
 af
te
r
su
cc
es
sfu
l d
ev
elo
pm
en
t o
f t
he
 dr
ug
 ca
nd
id
at
e w
ith
ex
te
rn
al 
se
rv
ice
 pr
ov
id
er
s
Ye
s, b
ec
au
se
 th
e d
ru
g w
ill 
be
 in
tro
du
ce
d i
nt
o t
he
 m
ar
ke
t b
y
th
e f
or
m
er
 an
d n
ew
 pa
re
nt
 co
m
pa
ny
H
Tr
an
sfe
r o
f t
he
 op
er
at
io
ns
 in
to
 a 
ne
w 
leg
al 
en
tit
y t
o c
om
-
pl
em
en
t a
nd
 fu
rth
er
 de
ve
lo
p t
he
 se
rv
ice
s
In
de
pe
nd
en
t c
om
pa
ny
 w
ith
 co
st
 co
m
pe
tit
ive
 se
rv
ice
ra
ng
e e
sp
ec
ial
ly 
fo
r t
he
 fo
rm
er
 pa
re
nt
 co
m
pa
ny
Ye
s, b
ec
au
se
 th
e s
er
vic
es
 ar
e w
id
ely
 us
ed
 by
 th
e f
or
m
er
pa
re
nt
 co
m
pa
ny
 as
 w
ell
 as
 ot
he
r c
us
to
m
er
s f
ro
m
 th
e
ph
ar
m
ac
eu
tic
al 
in
du
st
ry
I
Tr
an
sfe
r o
f t
he
 dr
ug
 ca
nd
id
at
es
 an
d o
th
er
 op
er
at
io
ns
in
to
 a 
ne
w 
leg
al 
en
tit
y t
o f
ur
th
er
 de
ve
lo
p t
he
 dr
ug
 ca
n-
di
da
te
s a
nd
 to
 re
st
ru
ct
ur
e t
he
 op
er
at
io
ns
M
er
ge
r w
ith
 a 
pu
bl
icl
y l
ist
ed
 bi
op
ha
rm
ac
eu
tic
al 
co
m
-
pa
ny
 in
 N
or
th
 A
m
er
ica
Ye
s, b
ec
au
se
 th
e d
ru
g c
an
di
da
te
 pr
oj
ec
ts
 ha
ve
 be
en
 fu
rth
er
de
ve
lo
pe
d a
nd
 on
e p
ro
du
ct
 ha
s a
lre
ad
y b
ee
n i
nt
ro
du
ce
d
in
to
 th
e m
ar
ke
t
J
Tr
an
sfe
r o
f t
he
 se
rv
ice
s i
nt
o a
 ne
w 
leg
al 
en
tit
y t
o
st
re
ng
th
en
 th
e s
er
vic
e o
ffe
rin
gs
In
de
pe
nd
en
t c
om
pa
ny
 w
ith
 in
te
gr
at
ed
 se
rv
ice
s f
or
 th
e
ph
ar
m
a i
nd
us
try
Ye
s, b
ec
au
se
 th
e s
er
vic
es
 ar
e w
id
ely
 us
ed
 by
 di
ffe
re
nt
cu
st
om
er
s f
ro
m
 th
e p
ha
rm
ac
eu
tic
al 
in
du
st
ry
In
te
rn
al
st
ar
t-u
ps
K L
Tr
an
sfe
r o
f t
he
 te
ch
no
lo
gy
 fr
om
 R&
D 
de
pa
rtm
en
t i
nt
o
a c
om
m
er
cia
l b
us
in
es
s u
ni
t
In
te
gr
at
io
n o
f t
he
 in
te
rn
al 
st
ar
t-u
p i
nt
o a
 bu
sin
es
s u
ni
t
of
 th
e c
he
m
ica
l c
om
pa
ny
Ye
s, b
ec
au
se
 th
e c
he
m
ica
l c
om
pa
ni
es
 co
m
m
er
cia
liz
ed
th
e t
ec
hn
ol
og
y b
y i
nt
ro
du
cin
g n
ew
 pr
od
uc
ts
 in
to
 th
e
m
ar
ke
t
Table 4b Technology transfer results (case study specific details).
